Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAS825 in monogenic IL-18 driven autoinflammatory diseases (randomized-withdrawal, placebo-controlled)
jRCT2041200077Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in autoinflammatory disease (AID), NLRC4-associated autoinflammatory disease (NLRC4-AID), X-linked lymphoproliferative disease type 2 (XLP2) and 2 more comparing MAS825 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Occurrence of disease flare during randomized-withdrawal period. Started Dec 2020; status: active, not recruiting.
02
Drugs
MAS825
03
Conditions
autoinflammatory disease (AID)NLRC4-associated autoinflammatory disease (NLRC4-AID)X-linked lymphoproliferative disease type 2 (XLP2)CDC42-associated autoinflammatory diseasenecrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on jRCT2041200077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041200077.